Development

New open access journal highlights methods and clinical trial results

The first issue of Elsevier's new open access journal Contemporary Clinical Trials Communications features a new method to make cancer clinical trials more effective, a better way of determining whether a trial was successful and a dashboard that helps patients enroll in trials. The journal is a spin-off of the well-established title Contemporary Clinical Trials.

There are many ways to carry out a clinical trial. Researchers need to think about the number of patients to enroll, the type of treatments to give and their frequency, among many other factors. Contemporary Clinical Trials Communications publishes methodology and statistics that answer these questions, helping researchers build on each other's work and design better trials.

For example, in the first issue of the journal, which is now available on ScienceDirect, researchers from Genentech Inc. and the Deerfield Institute describe a new trial design that helps researchers take into account delayed effects of immune-oncology treatments.

"I trust that the readers will find the journal a valuable source of recent advancements in clinical trials," said Dr. Zhezhen Jin, co-Editor-in-Chief of Contemporary Clinical Trials Communications and Professor of Biostatistics at Columbia University in New York. He also explained that this knowledge can "facilitate the design, conduct and analysis of their trials."

The journal also aims to tackle the problem of publication bias towards positive results by making all trial data open access.

"A major objective of the journal is to reduce publication bias, which is a major issue in the field of clinical trials," said Dr. Zheng Su, co-Editor-in-Chief of Contemporary Clinical Trials Communications and VP at the Deerfield Institute in New York.

There are two main approaches to clinical trials: randomized and non-randomized. In randomized trials, the participants do not know whether they are receiving the treatment or a placebo. In non-randomized trials, the participants are often all given the treatment. Many clinical trials journals only publish randomized trials, but Contemporary Clinical Trials Communications will publish both.

"There are several existing clinical trials journals that either give preferential treatment to positive trial results due to their perceived higher significance, or focus only on randomized trials," added Dr. Jin. "In contrast, Contemporary Clinical Trials Communications provides a platform for trialists around the world to share their knowledge on all aspects of clinical trials. We're making scientifically valid and technically sound original research findings freely accessible regardless of their perceived importance or impact."

Contemporary Clinical Trials Communications is now open for submissions. The first issue is published on ScienceDirect.

About Contemporary Clinical Trials Communications
Contemporary Clinical Trials Communications is an international, peer-reviewed, open access journal that publishes articles on all aspects of clinical trials, including design, conduct, analysis, regulation and ethics. Articles appeal to a wide range of disciplines. Contemporary Clinical Trials Communications strives to increase the transparency of medical research and reduce publication bias by publishing scientifically valid original research findings, irrespective of their perceived importance, significance or impact.

About Elsevier
Elsevier is a world-leading provider of information solutions that enhance the performance of science, health, and technology professionals, empowering them to make better decisions, deliver better care, and sometimes make groundbreaking discoveries that advance the boundaries of knowledge and human progress. Elsevier provides web-based, digital solutions - among them ScienceDirect, Scopus, Elsevier Research Intelligence and ClinicalKey - and publishes over 2,500 journals, including The Lancet and Cell, and more than 33,000 book titles, including a number of iconic reference works. Elsevier is part of RELX Group plc, a world-leading provider of information solutions for professional customers across industries.

Most Popular Now

New antibiotic Zavicefta approved i…

AstraZeneca today announced that the European Commission (EC) has granted marketing authorisation for Zavicefta (ceftazidime-avibactam, previously known as CAZ AVI), a ne...

Read more

Novo Nordisk and Aarhus University …

Novo Nordisk and Aarhus University's Science and Technology faculty today signed a collaboration agreement to strengthen protein technology research and development. Unde...

Read more

AstraZeneca enters licensing agreem…

AstraZeneca today announced that it has entered into agreements that support its strategic focus on three main therapy areas; Respiratory, Inflammation and Autoimmunity, ...

Read more

Novartis adds bispecific antibodies…

Today Novartis announced that it has entered into a collaboration and licensing agreement with Xencor for the development of bispecific antibodies for treating cancer. Th...

Read more

Bristol-Myers Squibb and PsiOxus Th…

Bristol-Myers Squibb Company (NYSE: BMY) and PsiOxus Therapeutics, Ltd. (PsiOxus) today announced an exclusive clinical collaboration agreement to evaluate the safety, to...

Read more

Bristol-Myers Squibb acquires Cormo…

Bristol-Myers Squibb Company (NYSE:BMY) and Cormorant Pharmaceuticals announced today that Bristol-Myers Squibb has acquired all of the outstanding capital stock of Cormo...

Read more

Sanofi Pasteur signs research agree…

Sanofi and its vaccines global business unit Sanofi Pasteur announced today a Cooperative Research and Development Agreement with the Walter Reed Army Institute of Resear...

Read more

FDA advances Precision Medicine Ini…

In support of the President’s Precision Medicine Initiative, the U.S. Food and Drug Administration has issued two draft guidances that, when finalized, will provide a fle...

Read more

Merck and Pfizer initiate Phase III…

Merck KGaA, Darmstadt, Germany, and Pfizer (NYSE: PFE) have announced the initiation of a Phase III study, JAVELIN Ovarian 100, to evaluate the efficacy and safety of ave...

Read more

Merck commits €1.5 million to the G…

Merck, a leading science and technology company, today announced it would continue to support the advancement of medical science in the field of fertility through the Gra...

Read more

Twisting and turning to target anti…

Researchers are getting closer to understanding how some natural antibiotics work so they can develop drugs that mimic them. A recent review commissioned by the British g...

Read more

A 'big data' approach to developing…

Scientists are starting to accumulate huge datasets on which genes mutate during cancer, allowing for a more systematic approach to "precision medicine." In a study publi...

Read more

Digest World Pharma Newsletter

Subscribe to our weekly Digest World Pharma Newsletter and stay updated on the latest World Pharma News. Subscribe now, it's free!

Pharmaceutical Companies

[ A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Z ]

© World Pharma News 2006 - 2016